Labcorp Announces Nationwide Availability of ColoSense®, the First FDA-Approved RNA-Based At-Home Colorectal Cancer Screening Test

Labcorp Announces Nationwide Availability of ColoSense®, the First FDA-Approved RNA-Based At-Home Colorectal Cancer Screening Test

PR Newswire

BURLINGTON, N.C. and ST. LOUIS, June 22, 2026

First FDA-approved, at-home screening test that uses RNA technology to detect biomarkers associated with colorectal cancer and advanced adenomasDesigned to reduce common barriers to at-home screening with a cleaner, simplified collection experience that minimizes sample handling Meets screening guidelines from the American Cancer Society (ACS) and National Comprehensive Cancer Network (NCCN)BURLINGTON, N.C. and ST. LOUIS, June 22, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the nationwide availability of ColoSense®, the only RNA-based at-home test for colorectal cancer (CRC) screening approved by the U.S. Food and Drug Administration (FDA). Offered through a commercial collaboration with test developer Geneoscopy, ColoSense expands Labcorp's comprehensive portfolio of colorectal cancer screening solutions. The test is now covered for eligible Medicare and Medicare Advantage beneficiariesi following the Centers for Medicare & Medicaid Services (CMS) update to the National Coverage Determination (NCD) in June, with additional commercial coverage also available.